All Huwe1-related plasmids in this study were constructed by PCR using pFastBac-Mule plasmid as templates. 
(FBS) and penicillin-streptomycin at 37℃ in a 5% CO2 incubat or. Transient plasmid DNA transfection was performed wit h Lipofectamine 2000 (Invitrogen) according to t he manufacturer's instructions.
For generating FH-CUL4B S3 HeLa stable cell line, S3 HeLa cells were trans fected with pcDNA 3.1-Flag-HA -CUL4B plasmid in 10 cm culture dishes. 24 h later, the cells were splitted in 60 mm plates and selected against hygromycin (700 μg/ml) for two weeks. Individual colonies were picked and expanded. Positive colonies were confirmed by western blotting and/or immunofluorescence with anti-HA monoclonal antibody.
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Cont rol, CUL4B, ROC1, UB C12 and DDB1 siRNA were synthesized from Invitrogen Inc or Genepharma Inc. The siRNA targeting sequences used are listed in table S2. Lipofectamine RNAi MA X (Invitrogen) was used for siRNA transfection. For transfection, cells were seeded into each well of a 6-well plate and subsequently transfected with a concent ration of 100 nM siRNA using Lipofectamine RNAi MA X. 48 h post transfection, proteins were extracted, and the lysates were examined by western blotting.
Cycloheximide (CHX) Chase Assay
293T cells were trans fected with pcDNA 3.1-Flag-HA -CUL4B wild type or mut atant (K859R)
constructs. 48 h after transfection, cells were treated with cycloheximide (100 μg/ml). HeLa cells were trans fected with siRNA targeting CUL4B, DDB1, ROC1 or UBC12 and treat ed as above. Cells were harvested at the indicated times, and protein levels were evaluated by western blotting.
Immunoprecipitation and Western Blotting
Cells were harvested and lysed with NE TENG -400 buffer (400 mM NaCl, 20 mM Tris-HCl, pH 7.4, 0.1% Nonidet P-40, 0.5 mM EDTA, 1.5 mM MgCl2, 10% Glycerol), with fres hly added phosphatase inhibitors and prot ease inhibitors cocktail (20 mM NaF, 1 mM Na3VO4, 1 mM PMSF, protease i nhibitor cocktail (P 8340, Sigma)). The lysates were diluted by adding 1. 68 volume of the lysate of NE TE NG-0 (20 mM Tris-HCl, pH 7. 4, 0.1% Nonidet P-40, 0.5 mM EDTA, 1.5 mM MgCl2, 10% Glycerol) to obtain a final concent ration of NaCl at 150 mM (NE TE NG-150: 150 mM NaCl, 20 mM Tris-HCl, pH 7.4, 0.1% Nonidet P-40, 0.5 mM EDTA, 1.5 mM MgCl2, 10% Glycerol). The diluted lysates were mixed with 30 ul of Protein-G beads and CUL4B antibody (ab67035, Abcam) or HUWE1 antibody (ab70161, abc am) at 4 °C overnight.
The prot eins bound to t he beads were washed three times with NE TE NG -150. The sample was eluted by 100 mM Glycine, pH 2. 
Ubiquitination Assays
For in vivo ubiquitination assay, pcDNA3-Myc-CUL4B wild type, K859R mut ant plasmids or CUL4B siRNA was co-transfected with HA-Ubiquitin and His-V 5 HUWE1 plasmids in 293T cells for 48 h. Cells were harvested and lysed in a phosphate/urea Buffer B (8 M Urea, 100 mM NaH2PO4，10 mM Tris pH 8.0; 20 mM imidazole, 1 mM β-mercaptoethanol ). The ubiquitinat ed proteins were precipitat ed with Ni-NTA agarose (QIAGE N), followed by four washes with Buffer C (8M Urea, 100 mM NaH2PO4， 10 mM Tris-HCl， pH 6.3). The precipitat ed proteins were eluted with Buffer E (8 M Urea, 100 mM NaH2PO4, 10 mM Tris-HCl, pH 4.0; 250 mM imidazole; 1 mM β-mercaptoethanol), and boiled with 4×Tris-acetate sample buffer, resolved by 3-8% Tris-acetate SDS-PAGE, and analyzed by immunoblotting with the indicated antibodies.
For in vitro ubiquitination assay, GS T-HUWE1 1-2500 (GS T-HW2500) recombinant prot ein was produced from SF9 cells and CRL4B complex was purified from HEK 293T c ells. For GS T-HW2500 expression and purification, Bac-to-B ac Baculovirus expression system (Invitrogen) was used according to the manufacturer's instructions. Briefly,
pFastBac1-GST-HUWE1-1-2500 plasmid was constructed by introducing a GS T-tag fus ed
HUWE1 DNA fragment encoding amino acids 1-2500 of HUWE1 prot ein into pFastBac1, and transformed into DH10B ac E.coli cells, selected with 50 ug/ml kanamycin, 7 ug/ml gentamicin, 10 ug/ml tetracycline, 100 ug/ml Bluo-gal, and 40 ug/ml IP TG. White colonies were c onfirmed by PCR and used for isolation of recombinant GST-HW2500 Bac omid DNA. SF9 cells were transfected with GST-HW2500 Bacomid DNA using Cellfectin (10362-100, Invitrogen) and baculovirus particles was generated and expanded. SF9 cells were infected with P2 stock
Pa ge 4 / 9 baculovirus GST-HW2500 for 72 h before harvest and lysed with SF9 lysis buffer (50 mM Hepes pH 8.0, 120 mM NaCl, 0.5% NP-40, 1 mM PMSF, proteinase inhibitor cocktails) for 40 minutes. The whole lysates were centrifuged at 12,000 rpm for 30 minutes. The rec ombinant protein GS T-HW2500 was pulled down with glutathione Sepharos e 4B (Amersham bioscience) and eluted with GST elution buffer (100 mM Tris-HCl, pH 8.0, 15 mg glutathione/ml).
For purification of CRL4B ligase complex, 293T cells were transfected with For in vitro ubiquitination assay, different combinations of E1 (100 ng, Boston Biochem), E2
(100 ng, Boston Biochem) and E3 (CRL4B ) were mixed with 100 ng of rec ombinant GS T-HW2500 substrate in a ubiquitin ligase reaction buffer (2 μg of HA-ubiquitin [Boston Biochem], 2 mM ATP, 5 mM MgCl2, 2 mM DTT, 50 mM Tris-HCl, pH 7.4). Reactions were carried out for 90 minutes at 30º C, terminated by boiling for 10 min in a S DS sample buffer, followed by 6% SDS-PAGE gel, and blotted with anti-HA and anti-HUWE1 antibodies.
DNA Damage Treatment
Cells were subjected to ionizing radiation using GS R-D1 137Cs gamma-irradiator (RPS Services Limited) at a dose rate of 1.8 Gy/min (8-Gy dose). For doxorubicin and etoposide treatments, cells were treated with either 0. 5 ug /ml doxorubicin (Dox) or 10uM etoposide (Eto).
The medium was changed after the treatment, and cells were incubated at 37°C to allow for DNA Repair.
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Cell Viability and Apoptosis Assays
Cell viability was assessed indirectly by MTT assay . The cells were cultured in t he 96-wells plates at a density of 5×10 4 ml -1 and treated with different concentration of doxorubicin, etoposide and cisplatin for 24 h. MTT was added to each well 4 h before termination of culture and incubat ed for 4 h at 37°C in 5% CO2. 10% S DS was then added to each well, followed by overnight incubation at 37°C and 5% CO2 to dissolve the dark blue crystal product. Each sample point was assayed with 4 replica points. Absorbance at 570 nm (A570) of the solubilized formazan was measured using a Bio-Tek Instruments (KC junior, USA) microplate reader to calculate inhibition rate for cell relative viability.
As for apoptosis assays, cells were suspended in PBS buffer and then washed, suspended in 100μl Annexin V-binding buffer. FITC-conjugated Annexin V and PI were used to stain the cells in each sample for 15 min at room temperature and analyzed by flow cytometry.
Gel analysis method with Image J 
CUL4B-1 AAGCCUAAAUUACCAGAAA

CUL4B-2 GGAGUUAUUUAGGGCUCAU
CUL4B (3'UTR)
GGUUCUUACACACCAUUAATT Target (GS T-HW2500) protein. GST-HW2500 was expressed and purified from SF9 cells infected with baculovirus GS T-HW2500 as descried in Experimental Procedures, and resolved by 4%-12% SDS-PAGE, followed by silver-staining.
